PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL. (Q43704561)

26 November 2017

title

PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL. (English)

1 reference

26 November 2017

S-H Shin

1

1 reference

26 November 2017

J-H Yoon

2

1 reference

26 November 2017

S-A Yahng

3

1 reference

26 November 2017

S-E Lee

4

1 reference

26 November 2017

B-S Cho

5

1 reference

26 November 2017

K-S Eom

6

1 reference

26 November 2017

Y-J Kim

7

1 reference

26 November 2017

H-J Kim

8

1 reference

26 November 2017

C-K Min

9

1 reference

26 November 2017

S-G Cho

10

1 reference

26 November 2017

D-W Kim

11

1 reference

26 November 2017

J-W Lee

12

1 reference

26 November 2017

W-S Min

13

1 reference

26 November 2017

C-W Park

14

1 reference

26 November 2017

S Lee

15

1 reference

26 November 2017

language of work or name

English

0 references

publication date

24 March 2014

1 reference

Bone Marrow Transplantation

26 November 2017

published in

1 reference

26 November 2017

volume

49

1 reference

26 November 2017

issue

6

1 reference

26 November 2017

page(s)

773-779

1 reference

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis fro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Peripheral-blood stem cells versus bone marrow from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.54

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

21 January 2018

1 reference

12 December 2020

Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia

1 reference

12 December 2020

Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia

1 reference

12 December 2020

Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies

1 reference

12 December 2020

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia

1 reference

12 December 2020

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

12 December 2020

Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors

1 reference

12 December 2020

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial

1 reference

12 December 2020

Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle

1 reference

12 December 2020

1994 Consensus Conference on Acute GVHD Grading

1 reference

12 December 2020

A randomised study of allogeneic transplantation with stem cells from blood or bone marrow

1 reference

12 December 2020

Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients

1 reference

12 December 2020

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

1 reference

12 December 2020

Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia

1 reference

12 December 2020

Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation

1 reference

12 December 2020

1 reference

12 December 2020

Allogeneic Stem Cell Transplantation in First Complete Remission Enhances Graft-versus-Leukemia Effect in Adults with Acute Lymphoblastic Leukemia: Antileukemic Activity of Chronic Graft-versus-Host Disease

1 reference

12 December 2020

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

1 reference

12 December 2020

No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2014.54

1 reference

Dimensions Publication ID

26 November 2017

1020008186

0 references

1 reference